The global market for ovarian cancer drugs expected to reach $10.1 billion by 2027, steadily growing at CAGR 17.1% over the forecast period, driven by continued uptake and expected launches of the approved PARP inhibitors, their impressive efficacy, long treatment duration and the large number of treatment opportunities in the first-line advanced setting.
Ovarian cancer is the 8th most common cancer among women and ranks 5th in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. The three major types of ovarian cancer are epithelial, accounting for 90% of cases, germ cell (3%), and sex cord-stromal (2%).
Most of the current information on factors associated with ovarian cancer risk is from studies of epithelial tumors. The strongest risk factor for ovarian cancer is a family history of breast or ovarian cancer. Modifiable factors associated with increased risk include use of menopausal hormone therapy and excess body weight.
- Ovarian cancer accounts for just 2.5% of all female cancer cases, but 5% of cancer deaths because of the disease’s low survival.
- For example, In 2015, it was present in 1.2 million women and resulted in 161,100 deaths worldwide. The risk of ovarian cancer increases in women with aged 55-64 years.
- In 2020, according to American Cancer Society estimates about 21,750 new cases of ovarian cancer will be diagnosed, whereas in 2018, an estimated ~22,240 patients were diagnosed with ovarian cancer in the United States alone.
Although advancing knowledge about ovarian cancer has been hindered by substantial disease heterogeneity and uncertainties about tumor tissues of origin, understanding of the disease has evolved rapidly in recent years, especially for epithelial tumors, the most common subtype.
- The most common preliminary diagnostic tests include blood test (CA-125, OVA-1, Inhibin B and Inhibin A), transvaginal ultrasound, CT scan or computerized tomography and biopsy.
- A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery. The Pap test does not test for ovarian cancer; it screens for cervical cancer.
Treatment usually includes some combination of surgery, radiation therapy, and chemotherapy. Treatment depends on the stage of the cancer; tumor characteristics and subtype; and the patient’s age, health, and preferences, but typically includes surgery and often chemotherapy (platinum- and taxane-based) and targeted therapy.
- Chemotherapy in ovarian cancer typically consists of platins, a group of platinum-based drugs, combined with non-platins.
- Common therapies can include paclitaxel, cisplatin, topotecan, doxorubicin, epirubicin, and gemcitabine.
- The vascular endothelial growth factor (VEGF) inhibitor, bevacizumab (Avastin; Roche/ Genentech), is approved (excluding the United States) as a first-line treatment in combination with standard chemotherapy.
- In Europe and the United States, bevacizumab is also approved for recurrent ovarian cancer.
- Currently, ovarian cancer drugs in active development (clinical phase II and III pipeline) includes Acalabrutinib, Atezolizumab, Avelumab, AZD1775, Cediranib, Epacadostat, Fosbretabulin, Gemogenovatucel-T, Lurbinectedin, Micellular paclitaxel, Mirvetuximab soravtansine, Trametinib, and Veliparib.
The global market for ovarian cancer drugs report provides market size ($million 2017 to 2027), market share, growth trends and forecast (CAGR%, 2021 to 2027).
The global ovarian cancer drugs market segmented by product (drug class/brand) – angiogenesis inhibitors [(Bevacizumab (Avastin)], PARP inhibitors [olaparib (Lynparza), rucaparib (Rubraca), niraparib (Zejula)], PDL1 inhibitors [avelumab (Bavencio), atezolizumab (Tecentriq)], pipeline analysis by target and development stage, and geography.
- The ovarian cancer market will experience significant growth over the next five years as novel therapies complete pivotal trials and make their way through regulatory agencies; the value of the US market is expected to expand at the fastest rate.
- Although angiogenesis inhibitors segment accounted for the majority of the market, this drug class is expected to capture a minority market share during the forecast period.
- Poly ADP-ribose polymerase (PARP) inhibition remains an attractive target for drugs in this indication with three PARP inhibitors already approved, but developers are also assessing newer immunological pathways.
- The PARP inhibitors are transforming the ovarian cancer treatment landscape. It is anticipated that the next big wave in ovarian cancer treatment after PARP inhibition monotherapy is combination therapy which is spurring development of other cancer immunotherapies in this space.
- The continued uptake of the approved PARP inhibitors (olaparib, rucaparib and niraparib) and the launch of two PDL1 inhibitors (avelumab and atezolizumab) will fuel impressive growth of the market in the coming years.
- AstraZeneca/Merck ’s leading PARP inhibitor Lynparza (olaparib) and GlaxoSmithKline’s challenger Zejula (niraparib) looks set to widen the market in ovarian cancer.
The global ovarian cancer drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.
In addition, the global ovarian cancer treatment market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major competitors operating in the global ovarian cancer treatment market and profiled in this report include AbbVie, Inc., AstraZeneca plc (Acerta Pharma), Boehringer Ingelheim GmbH, Chugai Pharmaceutical Co., Ltd., Clovis Oncology, Five Prime Therapeutics, Inc., GlaxoSmithKline plc (Tesaro), Gradalis, Inc., Incyte Corporation, MacroGenics, Inc., Mateon Therapeutics, Inc., Merck & Co., Inc., Novartis AG, Novogen Limited, Oasmia Pharmaceuticals, Inc., Pfizer, Inc., PharmaMar S.A, and Roche Holding AG.
- Product (Drug Class/Brand)
- Angiogenesis Inhibitors
- Bevacizumab (Avastin)
- Poly (ADP Ribose) Polymerase (PARP) Inhibitors
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Niraparib (Zejula)
- Programmed Cell Death Protein 1 Ligand 1 (PDL1) Inhibitors
- Avelumab (Bavencio)
- Atezolizumab (Tecentriq)
- Angiogenesis Inhibitors
- Pipeline Analysis by Target and Development Stage
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LATAM)
- Rest of the World
- Company Profiles
- AbbVie, Inc.
- AstraZeneca plc (Acerta Pharma)
- Boehringer Ingelheim GmbH
- Chugai Pharmaceutical Co., Ltd.
- Clovis Oncology
- Five Prime Therapeutics, Inc.
- GlaxoSmithKline plc (Tesaro)
- Gradalis, Inc.
- Incyte Corporation
- MacroGenics, Inc.
- Mateon Therapeutics, Inc.
- Merck & Co., Inc.
- Novartis AG
- Novogen Limited
- Oasmia Pharmaceuticals, Inc.
- Pfizer, Inc.
- PharmaMar S.A
- Roche Holding AG
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/